SU056 is a YB-1 inhibitor. SU056 induces cycle arrest and apoptosis in ovarian cancer cells, and inhibits cell migration of ovarian cancer cells. SU056 interacts with YB-1 and inhibits its associated downstream proteins and pathways. SU056 enhances the cytotoxic effects of paclitaxel .

Physicochemical Properties

Molecular Formula	C20H16FNO5
Molecular Weight	369.343149185181
Exact Mass	369.101
CAS #	2376580-08-2
PubChem CID	155351586
Appearance	White to off-white solid powder
LogP	2.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	3
Heavy Atom Count	27
Complexity	640
Defined Atom Stereocenter Count	0
SMILES	N1(CCO)C2C(=CC3OCOC=3C=2)C(C2=CC=CC(F)=C2)C2C(=O)OCC1=2
InChi Key	WVJVLSHRAJOEEW-UHFFFAOYSA-N
InChi Code	InChI=1S/C20H16FNO5/c21-12-3-1-2-11(6-12)18-13-7-16-17(27-10-26-16)8-14(13)22(4-5-23)15-9-25-20(24)19(15)18/h1-3,6-8,18,23H,4-5,9-10H2
Chemical Name	8-(3-fluorophenyl)-2-(2-hydroxyethyl)-5,12,14-trioxa-2-azatetracyclo[7.7.0.03,7.011,15]hexadeca-1(16),3(7),9,11(15)-tetraen-6-one
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	YB-1[1]
ln Vitro	SU056 (between 0 and 10 μM, for 48 hours) stops OVCAR3/4/5/8, SKOV3, and ID8 cells from growing [1]. OVCAR-8 and ID8 cell colony formation is dose-dependently inhibited by SU056 (1 μM, 5-8 days) [1]. OVCAR8, SKOV3, and ID8 cells are arrested in sub-G1 and G1 phases by SU056 (1–5 μM, 6 hours) [1]. OVCAR8, SKOV3, and ID8 cell migration is inhibited by SU056 (0-1 μM, 12 hours) [1]. OVCAR8, SKOV3, and ID8 cells undergo apoptosis in response to SU056 (0–5 μM, 24 h) [1]. In OVCAR8 cells, SU056 (1–5 μM, 12 h) suppresses the production of PMSB2, SUMO2, YB-1, and TMSB10 proteins [1]. Paclitaxel (HY-B0015) (0.1, 0.5, and 1 nM) had its cytotoxic effects enhanced by SU056 (0.1, 0.5, and 1 μM, 48 hours)[1].
ln Vivo	In mice implanted with ID8 cells, SU056 (20 mg/kg, i.p.) reduces the formation of tumors [1]. In immunodeficient mice implanted with ovarian cancer cells (OVCAR8), SU056 (10 mg/kg, intraperitoneal injection, daily) in combination with Paclitaxel (Paclitaxel.html" target="_blank" xstyle="color: #6a4b92; font-weight:bold;">HY-B0015) (5 mg/kg, intraperitoneal injection, weekly) inhibits tumor growth, and the effect is more evident than administration alone [1].
Cell Assay	Cell Viability Assay[1] Cell Types: OVCAR3/4/5/8, SKOV3 and ID8 cells Tested Concentrations: 0-10 μM approximately Incubation Duration: 48 h Experimental Results: Inhibited cell growth with IC50 values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM. Cell Migration Assay [1] Cell Types: OVCAR8, SKOV3, and ID8 cells Tested Concentrations: 0, 0.5, 1 μM Incubation Duration: 12 h Experimental Results: Dose-dependently inhibited cell migration. Western Blot Analysis[1] Cell Types: OVCAR8 cell Tested Concentrations: 1-5 μM Incubation Duration: 12 h Experimental Results: Dose- dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins.
Animal Protocol	Animal/Disease Models: C57BL/6 mice implanted (sc) with luciferase-expressing ID8 cells[1] Doses: 20 mg/kg Route of Administration: intraperitoneal (ip)injection Experimental Results: diminished the tumor weight by 2-fold, and is well-tolerated. diminished the lung metastases. Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample).
References	[1]. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem Biol. 2021 Aug 19;28(8):1206-1220.e6.

Solubility Data

Solubility (In Vitro)

DMSO : 50 mg/mL (135.38 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.5 mg/mL (6.77 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 5 mg/mL (13.54 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.7075 mL	13.5377 mL	27.0753 mL
	5 mM	0.5415 mL	2.7075 mL	5.4151 mL
	10 mM	0.2708 mL	1.3538 mL	2.7075 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.